Webinar

FROM MULTIPLE MYELOMA
TO GAUCHER DISEASE

SETTING THE NEW STANDARDS

01.10 18h30

QUINTA-FEIRA

1. Your choice for therapy of RRMM patients is often driven by:

Data from RCTs

Real-world evidence data

Patient choice

Fitness and comorbidities

2. How important do you think RWE is in current clinical pratice?

Very important. They may have an influence on my clinical pratice

Important but will not influence my clinical pratice

Relative important / interesting

Not important

WELCOME

KEYNOTE SPEAKERS

C-APROM/PT//0479 Data de Prep.: Setembro 2020

Takeda – Farmaceuticos Portugal, Lda., Rua dos Malhoes, no 5, Edificio Q56, D. Pedro I, Piso 3, 2770 071 Paco de Arcos, Portugal,
NIPC: 502 801 204 Registada na CRC de Cascais sob mesmo numero; T +351 21 120 14 57; F +351 21 120 14 56.

Webinar

FROM MULTIPLE MYELOMA TO GAUCHER DISEASE

SETTING THE NEW STANDARDS

01.10

18h30

QUINTA-FEIRA

WELCOME

KEYNOTE SPEAKERS

FROM MULTIPLE MYELOMA
TO GAUCHER DISEASE